← Back to Clinical Trials
Recruiting NCT04593498

Excessive Supraventricular Activity and Atrial Fibrillation

Trial Parameters

Condition Atrial Fibrillation
Sponsor Karolinska Institutet
Study Type OBSERVATIONAL
Phase N/A
Enrollment 250
Sex ALL
Min Age 70 Years
Max Age 89 Years
Start Date 2022-11-01
Completion 2026-12-31
Interventions
Holter recordingEchocardiography (Echo)Blood sample

Brief Summary

The aim of the proposed study is to determine if individuals with excessive supraventricular ectopic activity (ESVEA) on Holter recording should be subjected to prolonged screening with Event loop recorder in order to detect previously undiagnosed Atrial fibrillation / flutter. Other biomarkers such as plasma biomarkers, high-end echocardiography and assessment of blood pressure and atrial stiffness will be studied and compared in ESVEA and control group as well as progression of atrial cardiomyopathy in ESVEA patients.

Eligibility Criteria

Inclusion Criteria: Patients with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats on a Holter recording. Exclusion Criteria: Age \< 70 years, \>89 years Atrial fibrillation / flutter Lifelong treatment with oral anticoagulant Patients with implantable cardiac device Congestive heart failure (CHF) with Ejection fraction (EF) ≤ 30% Severe valvular heart disease

Related Trials